Pages with the fewest revisions
Jump to navigation
Jump to search
Showing below up to 50 results in range #44,151 to #44,200.
- Anterior spinal veins (2 revisions)
- Anterior superior alveolar arteries (2 revisions)
- Anterior tibial artery (2 revisions)
- Anterior tibial recurrent artery (2 revisions)
- Anterior tympanic artery (2 revisions)
- Anterior ulnar recurrent artery (2 revisions)
- Anterolateral central arteries (2 revisions)
- Anthelmintic (2 revisions)
- Anthocyans (2 revisions)
- Anthony Adducci (2 revisions)
- Anthracycline (2 revisions)
- Anthrax surgey (2 revisions)
- Anthropometry (2 revisions)
- Anthroposophical medicine (2 revisions)
- Anti-Müllerian hormone receptor (2 revisions)
- Anti-neutrophil cytoplasmic antibody (2 revisions)
- Anti-smooth muscle antibody (2 revisions)
- Antianalgesia (2 revisions)
- Antiandrogen (2 revisions)
- Antiangiogenic (2 revisions)
- Antibiotic sensitivity (2 revisions)
- Antibody-Directed Enzyme Prodrug Therapy (2 revisions)
- Anticholinergic (2 revisions)
- Anticoagulation in patients with dilated cardiomyopathy (2 revisions)
- Anticonvulsant (2 revisions)
- Antidiarrhoeal (2 revisions)
- Antiemetic (2 revisions)
- Antifibrinolytic (2 revisions)
- Antifreeze (2 revisions)
- Antifungal drug (2 revisions)
- Antigen-presenting cell vaccine (2 revisions)
- Antimitochondrial antibodies (2 revisions)
- Antimony pentafluoride (2 revisions)
- Antimony pentasulfide (2 revisions)
- Antimycin A (2 revisions)
- Antineoplastic (2 revisions)
- Antineoplaston (2 revisions)
- Antinuclear antibodies (2 revisions)
- Antiprotozoal agent (2 revisions)
- Antipruritic (2 revisions)
- Antisense RNA (2 revisions)
- Antiseptic (2 revisions)
- Antiserum (2 revisions)
- Antispasmodic (2 revisions)
- Antistaphylococcal penicillins (2 revisions)
- Antistreptolysin O titer (2 revisions)
- Antithrombin III deficiency case study one (2 revisions)
- Antithrombin III deficiency classification (2 revisions)
- Antithrombin III deficiency cost-effectiveness of therapy (2 revisions)
- Antithrombin III deficiency future or investigational therapies (2 revisions)